15 Stocks That Will Go to The Moon According to Analysts

Page 10 of 14

5. Genmab A/S (NASDAQ:GMAB)

Average Upside Potential: 50.14%

Number of Hedge Fund Holders: 19

Genmab A/S (NASDAQ:GMAB) is a biotechnology company developing antibody products for the treatment of cancer and other serious diseases. Through differentiated and innovative antibody therapeutics, the company aims to improve the lives of people.

The fast-growing international biotech has pioneered antibody-based medicines for 25 years. Its key strengths and differentiators include a world-class antibody biology knowledge, a pipeline featuring potential best-in-class and first-in-class therapies, in-house expertise with a track record of creating successful strategic partnerships, and the firm’s discovery and development engine featuring proprietary technologies enabling the creation of a world-class pipeline.

Genmab A/S (NASDAQ:GMAB) is currently striving to achieve its 2030 vision of being a fully integrated biotech innovation powerhouse. In 2024, the company marked a major milestone towards that target, with the acquisition of ProfoundBio, enhancing its long-term growth potential and giving it worldwide rights to three clinical candidates and novel antibody-drug conjugate platforms.

Page 10 of 14